Allied Market Research
Loading...
0
New
New
2021
Enzyme Replacement Therapy Market

Enzyme Replacement Therapy Market by Product (Agalsidase Beta, Imiglucerase, Velaglucerase Alfa, Idursulfase, Galsulfase, Laronidase, and Others), Disease (Gaucher Disease, Fabry Disease, Pompe Disease, Mucopolysaccharidosis, Exocrine Pancreatic Insufficiency (EPI), and Others), and End User (Hospitals and Infusion Centers & Home Healthcare Setting): Global Opportunity Analysis and Industry Forecast, 2021–2030

A10949
Pages: 280
Sep 2021 | 458 Views
   
Author(s) : Smita Nerkar , Onkar Sumant
Tables: 126
Charts: 55
  • Formats*:

  • SIngle User License, Five User
    License & Enterprise User License

  • Data Pack Excel License

  • IComes with the additional cost
    of $2500.00 contact sales.

 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Enzyme Replacement Therapy Market

Request Now !

Enzyme Replacement Therapy Market Overview

The enzyme replacement therapy market size was valued at $7,780.69 million in 2020, and is projected to reach $15,166.34 million by 2030, registering a CAGR of 8.3% from 2021 to 2030. Enzyme replacement therapy (ERT) is carried out to replace a missing or deficient enzyme in a person with an inherited enzyme deficiency syndrome. It replenishes the deficient enzymes in the patient’s body either through the intravenous (IV) or oral routes of administration. The IV route is widely accepted by people in which the replacement enzyme is administered directly into the bloodstream through a controlled drip of fluids.

The COVID-19 pandemic is an unprecedented global public health challenge and is anticipated to have a negative impact on the enzyme replacement therapy market. The continuous spread of the COVID-19 pandemic and the measures taken by the governments of various countries have affected, and could continue to affect, the businesses, including future disruptions to supply chain and the manufacture or shipment of drug substance and finished drug products. In addition, has resulted in decreased public mobility, as well as impacted the diagnostic industries. Several diagnostic procedures and therapies that are non-emergent were put on hold to prevent the transmission of the novel coronavirus.

The missing enzyme is replaced by infusions of an enzyme that is purified from human or animal tissue or blood or produced by novel recombinant DNA techniques. The enzyme is altered to allow for a longer half-life; more potent activity; resistance to degradation; or targeting a specific organ, tissue, or cell type. By receiving these enzyme replacements, the body is able to successfully perform the functions inhibited by the deficiency. Enzyme replacement therapies are intended to increase the concentration of enzymes but not for modifying underline root cause of the disease. The first effective treatment with ERT was performed in patients with Gaucher disease, and in last 15 years ERT has become available for other lysosomal storage disorders, including some types of mucopolysaccharidoses (MPS).

Enzyme-Replacement-Therapy-Market-2021-2030

Get more information on this report : Request Sample Pages

The growth of the global enzyme replacement therapy market is majorly driven by rise in prevalence of chronic and life-threatening lysosomal storage diseases such as Gaucher, Pompe, Fabry, and scid. Furthermore, the initiatives taken by the government to increase awareness among people about the availability of ERT is expected to notably contribute toward the growth of the global market. However, high treatment cost and the side effects associated with the therapy significantly hamper the growth of the enzyme replacement therapy market.

New developments in therapies and increase in product pipeline analysis are expected to provide remunerative opportunities for the expansion of the enzyme replacement therapy market. In addition, the healthcare industry in emerging economies is developing at a significant rate, due to surge in demand for enhanced healthcare services, significant investments by government to improve healthcare infrastructure, and development of the medical tourism industry in emerging countries.

The global enzyme replacement therapy market is segmented into product, disease type, end user, and region. Depending on product, the market is categorized into agalsidase beta, imiglucerase, velaglucerase alfa, idursulfase, galsulfase, laronidase, and others. On the basis of disease type, it is segregated into Gaucher disease, Fabry disease, Pompe disease, mucopolysaccharidosis, exocrine pancreatic insufficiency (EPI), and others. By end user, it is fragmented into hospitals and infusion centers & home healthcare setting. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.                  

COVID-19 Impact

Coronavirus (COVID-19) was recognized in late December in Hubei province of Wuhan city in China. This highly contagious disease, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted among humans. The COVID-19 pandemic has resulted in nationwide lockdown, thereby impacting every industry vertical. According to the report of the United Nations Human Rights, the COVID-19 pandemic has threatened all the members of the society. As a result, health care systems are affected, and the effective delivery of medical care and treatment to all patients have become a challenge worldwide. The COVID-19 pandemic is an unprecedented global public health challenge. During the pandemic, global healthcare systems faced many difficult challenges due to severe shortage of hospital beds & medical equipment. The impact of COVID-19 on 3D enzyme replacement therapy was negative during pandemic. Lysosomal storage diseases are considered to be high risk due to respiratory, renal, and cardiac involvement. For some types of MPS, ERT has been shown to improve respiratory and cardiac function, alleviate organomegaly, improve range of motion, and provide a better health-related quality of life. Enzyme replacement therapy in Pompe disease (glycogen storage disease type 2) improves cardiomyopathy and cardiac functions. It has been observed that it can reduce neuropathic pain and alleviates gastrointestinal symptoms and improves pulmonary functions in Fabry disease. The COVID-19 pandemic has resulted in decreased public mobility, as well as impacted the diagnostic industries. Several diagnostic procedures and therapies that are non-emergent were put on hold to prevent the transmission of the novel coronavirus. Unfortunately, scheduled ERT’s during COVID-19 were disrupted due the stringent lockdown norms. Lately, there is not sufficient personal protective equipment (PPE) for hospital workers on the front lines during the global health crisis. Hospitals were under pressure by the increasing number of patients and lack of personal protective equipment, including face masks, gloves, eye protection, and clothing.

Product segment review

Depending on product, the agalsidase beta segment dominated the enzyme replacement therapy market, due to rise in prevalence of chronic and life-threatening lysosomal storage diseases.

Enzyme Replacement Therapy Market
By Product

Your browser does not support the canvas element.

Others segment held a dominant position in 2020 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

Disease segment review

On the basis of disease, the mucopolysaccharidosis segment was the major revenue contributor, owing to increase in incidence of rare diseases.

Enzyme Replacement Therapy Market
By Disease

Your browser does not support the canvas element.

Mucopolysaccharidosis segment is projected as one of the most lucrative segment.

Get more information on this report : Request Sample Pages

End-user segment review

By end user, the hospitals segment held the largest market share in 2020, and is expected to continue this trend during the forecast period. This is attributed to the fact that people get more support from healthcare professionals & experts, closer monitoring, greater safety, and availability of trained professionals having utmost experience in performing critical infusions..

Enzyme Replacement Therapy Market
By End User

Your browser does not support the canvas element.

Hospitals segment held a dominant position in 2020 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

Region segment review

North America is serves as the prominent market for enzyme replacement therapy, and is expected to dominate throughout the forecast period. This is attributed to the availability of infusion centers, increase in acceptance of newer therapies, and rise in prevalence of enzyme deficiency in the region.

Enzyme Replacement Therapy Market
By Region

2030
North America 
Europe
Asia-pacific
Lamea

North America was holding a dominant position in 2020 and would continue to maintain the lead over the analysis period.

Get more information on this report : Request Sample Pages

Key Market Players

  • Abbvie Inc.
  • Astrazeneca Plc
  • Biomarin Pharmaceutical In
  • Chiesi Farmaceutici S.P.A.
  • Digestive Care, Inc.
  • Leadiant Biosciences, Inc.
  • Nestle Health Science
  • Pfizer Inc.
  • Sanofi
  • Takeda Pharmaceuticals

Key Benefits For Stakeholders

  • This report provides a detailed quantitative analysis of the current enzyme replacement therapy market trends and forecast estimations from 2020 to 2030, which assists to identify the prevailing market opportunities.
  • An in-depth market analysis includes analysis of various regions, which is anticipated to provide a detailed understanding of the current trends to enable stakeholders formulate region-specific plans.
  • A comprehensive analysis of factors that drive and restrain the growth of the global is provided.
  • The projections in this report are made by analyzing the current trends and future market potential from 2021 to 2030, in terms of value.
  • An extensive analysis of various regions provides insights that are expected to allow companies to strategically plan their business moves.
  • Key market players within the enzyme replacement therapy market are profiled in this report and their strategies are analyzed thoroughly, which helps in understanding competitive outlook of the enzyme replacement therapy market.

Key Market Segments

By Product

  • Agalsidase Beta      
  • Imiglucerase 
  • Velaglucerase Alfa
  • Idursulfase
  • Galsulfase
  • Laronidase
  • Others

By Disease

  • Gaucher Disease     
  • Fabry Disease         
  • Pompe Disease        
  • Mucopolysaccharidosis      
  • Exocrine Pancreatic Insufficiency (EPI)    
  • Others

By End User

  • Hospitals
  • Infusion Centers & Home Healthcare Setting  

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • Italy
    • France
    • UK
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
 

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments

1.3.1.List of key players profiled in the report

1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top investment pockets
3.2.2.Top winning strategies

3.3.Porter’s five force analysis
3.4.Top player positioning, 2020

3.5.Market dynamics

3.5.1.Drivers

3.5.1.1.Rise in the prevalence of rare diseases
3.5.1.2.Availability of a wide range of enzyme replacement therapy
3.5.1.3.Increasing Government initiatives for rare diseases

3.5.2.Restraint

3.5.2.1.High cost of  the treatment

3.5.3.Opportunity

3.5.3.1.New developments in therapies coupled with growing opportunities in emerging market

3.5.4.Impact analysis

3.6.COVID-19 impact analysis on the Enzyme replacement therapy market

CHAPTER 4:ENZYME REPLACEMENT THERAPY MARKET, BY PRODUCT

4.1.Overview

4.1.1.Market size and forecast

4.2.Agalsidase Beta

4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.2.1.Agalsidase beta by end users
4.2.3.Market analysis, by country

4.3.Imiglucerase

4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region
4.3.2.1.Imiglucerase by end users
4.3.3.Market analysis, by country

4.4.Velaglucerase alfa

4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by region
4.4.2.1.Velaglucerase alfa by end users
4.4.3.Market analysis, by country

4.5.Idursulfase

4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast, by region

4.5.2.1.Idursulfase by end users

4.5.3.Market analysis, by country
Source: Primary & Secondary Research and AMR Analysis

4.6.Galsulfase

4.6.1.Key market trends, growth factors, and opportunities
4.6.2.Market size and forecast, by region

4.6.2.1.Galsulfase by end users

4.6.3.Market analysis, by country
Source: Primary & Secondary Research and AMR Analysis

4.7.Laronidase

4.7.1.Key market trends, growth factors, and opportunities
4.7.2.Market size and forecast, by region

4.7.2.1.Laronidase by end users

4.7.3.Market analysis, by country
Source: Primary & Secondary Research and AMR Analysis

4.8.Others

4.8.1.Key market trends, growth factors, and opportunities
4.8.2.Market size and forecast, by region

4.8.2.1.Others by end users

4.8.3.Market analysis, by country
Source: Primary & Secondary Research and AMR Analysis

CHAPTER 5:ENZYME REPLACEMENT THERAPY, BY DISEASE TYPE

5.1.Overview

5.1.1.Market size and forecast

5.2.Gaucher disease

5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country

5.3.Fabry Disease

5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country

5.4.Pompe Disease

5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country

5.5.Mucopolysaccharidosis

5.5.1.Market size and forecast, by region
5.5.2.Market analysis, by country

5.6.Exocrine pancreatic insufficiency EPI

5.6.1.Market size and forecast, by region
5.6.2.Market analysis, by country

5.7.Others

5.7.1.Market size and forecast, by region
5.7.2.Market analysis, by country

CHAPTER 6:ENZYME REPLACEMENT THERAPY MARKET, BY END USER

6.1.Overview

6.1.1.Market size and forecast

6.2.Hospitals

6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country

6.3.Infusion Centers & Home Healthcare Setting

6.3.1.Market size and forecast, by region
6.3.2.Market analysis, by country

CHAPTER 7:ENZYME REPLACEMENT THERAPY MARKET, BY REGION

7.1.Overview

7.1.1.Market size and forecast

7.2.North America

7.2.1.Key market trends, growth factors, and opportunities
7.2.2.North America  enzyme replacement therapy market, by product
7.2.3.North America  infection surveillance services  market, by disease type
7.2.4.North America  infection surveillance services  market, by end user
7.2.5.Market size and forecast, by country

7.2.5.1.U.S. Enzyme replacement therapy market, by product
7.2.5.2.U.S. Enzyme replacement therapy market, by disease
7.2.5.3.U.S. Enzyme replacement therapy market, by end user
7.2.5.4.Canada Enzyme replacement therapy market, by product type
7.2.5.5.Canada Enzyme replacement therapy market, by disease type
7.2.5.6.Canada Enzyme replacement therapy market, by end user
7.2.5.7.Mexico Enzyme replacement therapy market, by product
7.2.5.8.Mexico Enzyme replacement therapy market, by disease type
7.2.5.9.Mexico Enzyme replacement therapy market, by end user

7.3.Europe

7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Europe infection surveillance services  market, by product
7.3.3.Europe infection surveillance services  market, by disease type
7.3.4.Europe infection surveillance services  market, by end user
7.3.5.Market size and forecast, by country

7.3.5.1.Germany Enzyme replacement therapy market, by product
7.3.5.2.Germany Enzyme replacement therapy market, by disease type
7.3.5.3.Germany Enzyme replacement therapy market, by end user
7.3.5.4.France Enzyme replacement therapy market, by product
7.3.5.5.France Enzyme replacement therapy market, by disease type
7.3.5.6.France Enzyme replacement therapy market, by end user
7.3.5.7.UK Enzyme replacement therapy market, by product
7.3.5.8.UK Enzyme replacement therapy market, by disease type
7.3.5.9.UK Enzyme replacement therapy market, by end user
7.3.5.10.Italy Enzyme replacement therapy market, by product
7.3.5.11.Italy Enzyme replacement therapy market, by disease type
7.3.5.12.Italy Enzyme replacement therapy market, by end user
7.3.5.13.Spain Enzyme replacement therapy market, by product
7.3.5.14.Spain Enzyme replacement therapy market, by disease type
7.3.5.15.Spain Enzyme replacement therapy market, by end user
7.3.5.16.Rest of Europe Enzyme replacement therapy market, by product
7.3.5.17.Rest of Europe Enzyme replacement therapy market, by disease type
7.3.5.18.Rest of Europe Enzyme replacement therapy market, by end user

7.4.Asia-Pacific

7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Asia-Pacific infection surveillance services  market, by product
7.4.3.Asia-Pacific infection surveillance services  market, by disease type
7.4.4.Asia-Pacific infection surveillance services  market, by end user
7.4.5.Market size and forecast, by country

7.4.5.1.Japan Enzyme replacement therapy market, by product
7.4.5.2.Japan Enzyme replacement therapy market, by disease type
7.4.5.3.Japan Enzyme replacement therapy market, by end user
7.4.5.4.China Enzyme replacement therapy market, by product
7.4.5.5.China Enzyme replacement therapy market, by disease type
7.4.5.6.China Enzyme replacement therapy market, by end user
7.4.5.7.Australia Enzyme replacement therapy market, by product
7.4.5.8.Australia Enzyme replacement therapy market, by disease type
7.4.5.9.Australia Enzyme replacement therapy market, by end user
7.4.5.10.India Enzyme replacement therapy market, by product
7.4.5.11.India Enzyme replacement therapy market, by disease type
7.4.5.12.India Enzyme replacement therapy market, by end user
7.4.5.13.South Korea Enzyme replacement therapy market, by product
7.4.5.14.South Korea Enzyme replacement therapy market, by disease type
7.4.5.15.South Korea Enzyme replacement therapy market, by end user
7.4.5.16.Rest of Asia-Pacific Enzyme replacement therapy market, by product
7.4.5.17.Rest of Asia-Pacific Enzyme replacement therapy market, by disease type

7.5.LAMEA

7.5.1.Key market trends, growth factors, and opportunities
7.5.2.LAMEA  infection surveillance services  market, by product
7.5.3.LAMEA infection surveillance services  market, by disease type
7.5.4.LAMEA infection surveillance services  market, by end user
7.5.5.Market size and forecast, by country

7.5.5.1.Brazil Enzyme replacement therapy market, by product
7.5.5.2.Brazil Enzyme replacement therapy market, by disease type
7.5.5.3.Brazil Enzyme replacement therapy market, by end user
7.5.5.4.Saudi Arabia Enzyme replacement therapy market, by product
7.5.5.5.Saudi Arabia Enzyme replacement therapy market, by disease type
7.5.5.6.Saudi Arabia Enzyme replacement therapy market, by end user
7.5.5.7.South Africa Enzyme replacement therapy market, by product
7.5.5.8.South Africa Enzyme replacement therapy market, by disease type
7.5.5.9.South Africa Enzyme replacement therapy market, by end user
7.5.5.10.Rest of LAMEA Enzyme replacement therapy market, by product
7.5.5.11.Rest of LAMEA Enzyme replacement therapy market, by disease type
7.5.5.12.Rest of LAMEA Enzyme replacement therapy market, by end user

CHAPTER 8:COMPANY PROFILES

8.1.ABBVIE INC.

8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Business performance
8.1.6.Key strategic moves and developments

8.2.ASTRAZENECA PLC (ASTRAZENECA)

8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.2.5.Business performance

8.3.BioMarin Pharmaceutical Inc.

8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Business performance
8.3.6.Key strategic moves and developments

8.4.Chiesi Farmaceutici S.P.A

8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance

8.5.Digestive Care, Inc.

8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Product portfolio

8.6.Leadiant Biosciences, Inc.

8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Key strategic moves and developments

8.7.NESTLE S.A. (Nestlé Health Science S.A.)

8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance

8.8.PFIZER, INC.

8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance

8.9.SANOFI S.A.

8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance
8.9.6.Key strategic moves and developments

8.10.Takeda Pharmaceutical Company Limited

8.10.1.Company overview
8.10.2.Operating business segments
8.10.3.Product portfolio
Takeda Pharmaceutical. offers the following enzyme replacement therapies:
8.10.4.Business performance
8.10.5.Key strategic moves and developments

LIST OF TABLES

TABLE 01.ENZYME REPLACEMENT THERAPY MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 02.AGALSIDASE BETA ENZYME REPLACEMENT THERAPY MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 03.ALGASIDAE BETA MARKET, BY END USER, 2020-2030($MILLION)
TABLE 04.IMIGLUCERASE MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 05.IMIGLUCERASE MARKET, BY END USER, 2020-2030($MILLION)
TABLE 06.ENZYME REPLACEMENT THERAPY DEVICES MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 07.VELAGLUCERASE ALFA MARKET, BY END USER, 2020-2030($MILLION)
TABLE 08.IDURSULFASE MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 09.IDURSULFASE MARKET, BY END USER, 2020-2030($MILLION)
TABLE 10.ENZYME REPLACEMENT THERAPY DEVICES MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 11.GALSULFASE MARKET, BY END USER, 2020-2030($MILLION)
TABLE 12.ENZYME REPLACEMENT THERAPY DEVICES MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 13.LARONIDASE MARKET, BY END USER, 2020-2030($MILLION)
TABLE 14.ENZYME REPLACEMENT THERAPY DEVICES MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 15.OTHERS MARKET, BY END USER, 2020-2030($MILLION)
TABLE 16.ENZYME REPLACEMENT THERAPY MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 17.GAUCHER DISEASE ENZYME REPLACEMENT THERAPY MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 18.FABRY DISEASE ENZYME REPLACEMENT THERAPY MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 19.POMPE DISEASE ENZYME REPLACEMENT THERAPY MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 20.MUCOPOLYSACCHARIDOSIS ENZYME REPLACEMENT THERAPY MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 21.EXOCRINE PANCREATIC INSUFFICIENCY ENZYME REPLACEMENT THERAPY MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 22.OTHERS ENZYME REPLACEMENT THERAPY MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 23.ENZYME REPLACEMENT THERAPY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 24.ENZYME REPLACEMENT THERAPY MARKET FOR HOSPITALS, BY REGION, 2020-2030 ($MILLION)
TABLE 25.INFUSION CENTERS & HOME HEALTHCARE SETTING ENZYME REPLACEMENT THERAPY MARKET FOR OTHERS, BY REGION, 2020-2030 ($MILLION)
TABLE 26.ENZYME REPLACEMENT THERAPY MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 27.NORTH AMERICA ENZYME REPLACEMENT THERAPY MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 28.NORTH AMERICA ENZYME REPLACEMENT THERAPY MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 29.NORTH AMERICA  INFECTION SURVEILLANCE SERVICES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 30.NORTH AMERICA ENZYME REPLACEMENT THERAPY MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 31.U.S. ENZYME REPLACEMENT THERAPY MARKET, BY PRODUCT, 2020–2030
TABLE 32.U.S. ENZYME REPLACEMENT THERAPY MARKET, BY DISEASE, 2020–2030
TABLE 33.U.S. ENZYME REPLACEMENT THERAPY MARKET, BY END USER, 2020–2030
TABLE 34.CANADA ENZYME REPLACEMENT THERAPY MARKET, BY PRODUCT, 2020–2030
TABLE 35.CANADA ENZYME REPLACEMENT THERAPY MARKET, BY DISEASE TYPE, 2020–2030
TABLE 36.CANADA ENZYME REPLACEMENT THERAPY MARKET, BY END USER, 2020–2030
TABLE 37.MEXICO ENZYME REPLACEMENT THERAPY MARKET, BY PRODUCT, 2020–2030
TABLE 38.MEXICO ENZYME REPLACEMENT THERAPY MARKET, BY DISEASE TYPE, 2020–2030
TABLE 39.MEXICO ENZYME REPLACEMENT THERAPY MARKET, BY END USER, 2020–2030
TABLE 40.EUROPE INFECTION SURVEILLANCE SERVICES MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 41.EUROPE ENZYME REPLACEMENT THERAPY MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 42.EUROPE ENZYME REPLACEMENT THERAPY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 43.EUROPE ENZYME REPLACEMENT THERAPY MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 44.GERMANY ENZYME REPLACEMENT THERAPY MARKET, BY PRODUCT, 2020–2030
TABLE 45.GERMANY ENZYME REPLACEMENT THERAPY MARKET, BY DISEASE TYPE, 2020–2030
TABLE 46.GERMANY ENZYME REPLACEMENT THERAPY MARKET, BY END USER, 2020–2030
TABLE 47.FRANCE ENZYME REPLACEMENT THERAPY MARKET, BY PRODUCT, 2020–2030
TABLE 48.FRANCE ENZYME REPLACEMENT THERAPY MARKET, BY DISEASE TYPE, 2020–2030
TABLE 49.FRANCE ENZYME REPLACEMENT THERAPY MARKET, BY END USER, 2020–2030
TABLE 50.UK ENZYME REPLACEMENT THERAPY MARKET, BY PRODUCT, 2020–2030
TABLE 51.UKENZYME REPLACEMENT THERAPY MARKET, BY INJURY TYPE, 2020–2030
TABLE 52.UK ENZYME REPLACEMENT THERAPY MARKET, BY END USER, 2020–2030
TABLE 53.ITALY ENZYME REPLACEMENT THERAPY MARKET, BY PRODUCT, 2020–2030
TABLE 54.ITALY ENZYME REPLACEMENT THERAPY MARKET, BY DISEASE TYPE, 2020–2030
TABLE 55.ITALY ENZYME REPLACEMENT THERAPY MARKET, BY END USER, 2020–2030
TABLE 56.SPAIN ENZYME REPLACEMENT THERAPY MARKET, BY PRODUCT, 2020–2030
TABLE 57.SPAIN ENZYME REPLACEMENT THERAPY MARKET, BY DISEASE TYPE, 2020–2030
TABLE 58.SPAIN ENZYME REPLACEMENT THERAPY MARKET, BY END USER, 2020–2030
TABLE 59.REST OF EUROPE ENZYME REPLACEMENT THERAPY MARKET, BY PRODUCT, 2020–2030
TABLE 60.REST OF EUROPE ENZYME REPLACEMENT THERAPY MARKET, BY DISEASE TYPE, 2020–2030
TABLE 61.REST OF EUROPE ENZYME REPLACEMENT THERAPY MARKET, BY END USER, 2020–2030
TABLE 62.ASIA-PACIFIC INFECTION SURVEILLANCE SERVICES MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 63.ASIA-PACIFIC INFECTION SURVEILLANCE SERVICES  MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 64.ASIA-PACIFIC INFECTION SURVEILLANCE SERVICES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 65.ASIA-PACIFIC ENZYME REPLACEMENT THERAPY MARKET, BY COUNTRY, 2020-2030($MILLION)
TABLE 66.JAPAN ENZYME REPLACEMENT THERAPY MARKET, BY PRODUCT, 2020–2030
TABLE 67.JAPAN ENZYME REPLACEMENT THERAPY MARKET, BY DISEASE TYPE, 2020–2030
TABLE 68.JAPAN ENZYME REPLACEMENT THERAPY MARKET, BY END USER, 2020–2030
TABLE 69.CHINA ENZYME REPLACEMENT THERAPY MARKET, BY PRODUCT, 2020–2030
TABLE 70.CHINA ENZYME REPLACEMENT THERAPY MARKET, BY DISEASE TYPE, 2020–2030
TABLE 71.CHINA ENZYME REPLACEMENT THERAPY MARKET, BY END USER, 2020–2030
TABLE 72.AUSTRALIA ENZYME REPLACEMENT THERAPY MARKET, BY PRODUCT, 2020–2030
TABLE 73.AUSTRALIA ENZYME REPLACEMENT THERAPY MARKET, BY DISEASE TYPE, 2020–2030
TABLE 74.AUSTRALIA ENZYME REPLACEMENT THERAPY MARKET, BY END USER, 2020–2030
TABLE 75.INDIA ENZYME REPLACEMENT THERAPY MARKET, BY PRODUCT, 2020–2030
TABLE 76.INDIA ENZYME REPLACEMENT THERAPY MARKET, BY DISEASE TYPE, 2020–2030
TABLE 77.INDIA ENZYME REPLACEMENT THERAPY MARKET, BY END USER, 2020–2030
TABLE 78.SOUTH KOREA ENZYME REPLACEMENT THERAPY MARKET, BY PRODUCT, 2020–2030
TABLE 79.SOUTH KOREA ENZYME REPLACEMENT THERAPY MARKET, BY DISEASE TYPE, 2020–2030
TABLE 80.SOUTH KOREA ENZYME REPLACEMENT THERAPY MARKET, BY END USER, 2020–2030
TABLE 81.REST OF ASIA-PACIFIC ENZYME REPLACEMENT THERAPY MARKET, BY PRODUCT, 2020–2030
TABLE 82.REST OF ASIA-PACIFIC ENZYME REPLACEMENT THERAPY MARKET, BY DISEASE TYPE, 2020–2030
TABLE 83.REST OF ASIA-PACIFIC ENZYME REPLACEMENT THERAPY MARKET, BY END USER, 2020–2030
TABLE 84.LAMEA INFECTION SURVEILLANCE SERVICES MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 85.LAMEA INFECTION SURVEILLANCE SERVICES  MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 86.LAMEA ENZYME REPLACEMENT THERAPY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 87.LAMEA ENZYME REPLACEMENT THERAPY MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 88.BRAZIL ENZYME REPLACEMENT THERAPY MARKET, BY PRODUCT, 2020–2030
TABLE 89.BRAZIL ENZYME REPLACEMENT THERAPY MARKET, BY DISEASE TYPE, 2020–2030
TABLE 90.BRAZIL ENZYME REPLACEMENT THERAPY MARKET, BY END USER, 2020–2030
TABLE 91.SAUDI ARABIA ENZYME REPLACEMENT THERAPY MARKET, BY PRODUCT, 2020–2030
TABLE 92.SAUDI ARABIA ENZYME REPLACEMENT THERAPY MARKET, BY DISEASE TYPE, 2020–2030
TABLE 93.SAUDI ARABIA ENZYME REPLACEMENT THERAPY MARKET, BY END USER, 2020–2030
TABLE 94.SOUTH AFRICA ENZYME REPLACEMENT THERAPY MARKET, BY PRODUCT, 2020–2030
TABLE 95.SOUTH AFRICA ENZYME REPLACEMENT THERAPY MARKET, BY DISEASE TYPE, 2020–2030
TABLE 96.SOUTH AFRICA ENZYME REPLACEMENT THERAPY MARKET, BY END USER, 2020–2030
TABLE 97.REST OF LAMEA ENZYME REPLACEMENT THERAPY MARKET, BY PRODUCT, 2020–2030
TABLE 98.REST OF LAMEA ENZYME REPLACEMENT THERAPY MARKET, BY DISEASE TYPE, 2020–2030
TABLE 99.REST OF LAMEA ENZYME REPLACEMENT THERAPY MARKET, BY END USER, 2020–2030
TABLE 100.ABBVIE INC: COMPANY SNAPSHOT
TABLE 101.ABBVIE INC: OPERATING SEGMENTS
TABLE 102.ABBVIE INC: PRODUCT TYPE PORTFOLIO
TABLE 103.ASTRAZENECA: COMPANY SNAPSHOT
TABLE 104.ASTRAZENECA: OPERATING SEGMENTS
TABLE 105.ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 106.BIOMARIN: COMPANY SNAPSHOT
TABLE 107.BIOMARIN: OPERATING SEGMENTS
TABLE 108.BIOMARIN: PRODUCT PORTFOLIO
TABLE 109.CHIESI FARMACEUTICI.: COMPANY SNAPSHOT
TABLE 110.CHIESI FARMACEUTICI: OPERATING SEGMENTS
TABLE 111.MERCK: PRODUCT TYPE PORTFOLIO
TABLE 112.DIGESTIVE CARE: COMPANY SNAPSHOT
TABLE 113.SANOFI: PRODUCT TYPE PORTFOLIO
TABLE 114.LEADIANT BIOSCIENCES: COMPANY SNAPSHOT
TABLE 115.LEADIANT BIOSCIENCES: PRODUCT TYPE PORTFOLIO
TABLE 116.NESTLE: COMPANY SNAPSHOT
TABLE 117.NESTLE: OPERATING SEGMENTS
TABLE 118.NESTLE: PRODUCT PORTFOLIO
TABLE 119.PFIZER INC: COMPANY SNAPSHOT
TABLE 120.PFIZER INC: PRODUCT TYPE PORTFOLIO
TABLE 121.SANOFI: COMPANY SNAPSHOT
TABLE 122.SANOFI: OPERATING SEGMENTS
TABLE 123.SANOFI: PRODUCT TYPE PORTFOLIO
TABLE 124.TAKEDA PHARMACEUTICAL: COMPANY SNAPSHOT
TABLE 125.BIODIEM: OPERATING SEGMENTS
TABLE 126.TAKEDA PHARMACEUTICAL: PRODUCT PORTFOLIO
 LIST OF FIGURES
FIGURE 01.ENZYME REPLACEMENT THERAPY MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2018–2021
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018–2021 (%)
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2018–2021
FIGURE 06.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
FIGURE 08.MODERATE THREAT OF SUBSTITUTES
FIGURE 09.MODERATE THREAT OF NEW ENTRANTS
FIGURE 10.MODERATE COMPETITIVE RIVALRY
FIGURE 11.TOP PLAYER POSITIONING, 2020
FIGURE 12.IMPACT ANALYSIS
FIGURE 13.COMPARATIVE SHARE ANALYSIS OF ENZYME REPLACEMENT THERAPY MEDICATION MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 14.COMPARATIVE SHARE ANALYSIS OF ENZYME REPLACEMENT THERAPY DEVICES MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 15.COMPARATIVE SHARE ANALYSIS OF ENZYME REPLACEMENT THERAPY DEVICES MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 16.COMPARATIVE SHARE ANALYSIS OF ENZYME REPLACEMENT THERAPY DEVICES MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 17.COMPARATIVE SHARE ANALYSIS OF ENZYME REPLACEMENT THERAPY DEVICES MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 18.COMPARATIVE SHARE ANALYSIS OF ENZYME REPLACEMENT THERAPY DEVICES MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 19.COMPARATIVE SHARE ANALYSIS OF ENZYME REPLACEMENT THERAPY DEVICES MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 20.COMPARATIVE SHARE ANALYSIS OF DIRECT ENZYME REPLACEMENT THERAPY MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 21.COMPARATIVE SHARE ANALYSIS OF INDIRECT ENZYME REPLACEMENT THERAPY MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 22.COMPARATIVE SHARE ANALYSIS OF INDIRECT ENZYME REPLACEMENT THERAPY MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 23.COMPARATIVE SHARE ANALYSIS OF INDIRECT ENZYME REPLACEMENT THERAPY MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 24.COMPARATIVE SHARE ANALYSIS OF INDIRECT ENZYME REPLACEMENT THERAPY MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 25.COMPARATIVE SHARE ANALYSIS OF INDIRECT ENZYME REPLACEMENT THERAPY MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 26.COMPARATIVE ANALYSIS OF ENZYME REPLACEMENT THERAPY MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 27.COMPARATIVE ANALYSIS OF ENZYME REPLACEMENT THERAPY MARKET FOR OTHERS, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 28.ABBVIE INC: REVENUE, 2018–2020 ($MILLION)
FIGURE 29.ABBVIE INC: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 30.ASTRAZENECA: REVENUE, 2018–2020 ($MILLION)
FIGURE 31.ASTRAZENECA: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 32.ASTRAZENECA: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 33.BIOMARIN: REVENUE, 2017–20219 ($MILLION)
FIGURE 34.BIOMARIN: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 35.CHIESI FARMACEUTICI: REVENUE, 2018–2020 ($MILLION)
FIGURE 36.CHIESI FARMACEUTICI: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 37.NESTLE: REVENUE, 2018–2020 ($MILLION)
FIGURE 38.NESTLE: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 39.NESTLE: REVENUE SHARE BY GEOGRAPHY, 2020 (%)
FIGURE 40.PFIZER INC: REVENUE, 2018–2020 ($MILLION)
FIGURE 41.PFIZER INC: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 42.SANOFI: REVENUE, 2018–2020 ($MILLION)
FIGURE 43.SANOFI: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 44.SANOFI: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 45.TAKEDA PHARMACEUTICAL: REVENUE, 2018–2020 ($MILLION)
FIGURE 46.TAKEDA PHARMACEUTICAL: REVENUE SHARE BY REGION, 2020 (%)


LIST OF FIGURES
FIGURE 01.TOP INVESTMENT POCKETS IN THE GLOBAL 3D PRINTING HEALTHCARE MARKET, 2020
FIGURE 02.TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION, 2018–2021(%)
FIGURE 03.TOP WINNING STRATEGIES:BY DEVELOPMENT, 2018-2021(%)
FIGURE 04.TOP WINNING STRATEGIES: BY COMPANY, 2018–2021 (%)
FIGURE 05.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 06.MODERATE THREAT OF NEW ENTRANTS
FIGURE 07.MODERATE THREAT OF SUBSTITUTION
FIGURE 08.HIGH INTENSITY OF RIVALRY
FIGURE 09.MODERATE BARGAINING POWER OF BUYERS
FIGURE 10.DISTRIBUTION OF TOP WINNING STRATEGIES, 2018-2021
FIGURE 11.PATENT ANALYSIS, BY REGION (2017–2020)
FIGURE 12.PATENT ANALYSIS, BY YEAR (2017–2020)
FIGURE 13.PATENT ANALYSIS, BY APPLICANT (2018–2020)
FIGURE 14.COMPARATIVE SHARE ANALYSIS OF 3D PRINTING IN HEALTHCARE MARKET FOR SYSTEMS BY COUNTRY, 2020 & 2030 (%)
FIGURE 15.COMPARATIVE SHARE ANALYSIS OF 3D PRINTING IN HEALTHCARE MARKET FOR MATERIALS BY COUNTRY, 2020 & 2030 (%)
FIGURE 16.3D PRINTING IN HEALTHCARE MARKET FOR POLYMER, 2020-2030 ($MILLION)
FIGURE 17.3D PRINTING IN HEALTHCARE MARKET FOR METALS & ALLOYS, 2020-2030 ($MILLION)
FIGURE 18.3D PRINTING IN HEALTHCARE MARKET FOR CERAMICS, 2020-2030 ($MILLION)
FIGURE 19.3D PRINTING IN HEALTHCARE MARKET FOR OTHERS, 2020-2030 ($MILLION)
FIGURE 20.COMPARATIVE SHARE ANALYSIS OF 3D PRINTING IN HEALTHCARE MARKET FOR SERVICES BY COUNTRY, 2020 & 2030 (%)
FIGURE 21.COMPARATIVE SHARE ANALYSIS OF 3D PRINTING IN HEALTHCARE MARKET FOR DROPLET DEPOSITION/FUSED DEPOSITION MODELING BY COUNTRY, 2020 & 2030 (%)
FIGURE 22.COMPARATIVE SHARE ANALYSIS OF 3D PRINTING IN HEALTHCARE MARKET FOR PHOTOPOLYMERIZATION BY COUNTRY, 2020 & 2030 (%)
FIGURE 23.COMPARATIVE SHARE ANALYSIS OF 3D PRINTING IN HEALTHCARE MARKET FOR LASER BEAM MELTING BY COUNTRY, 2020 & 2030 (%)
FIGURE 24.COMPARATIVE SHARE ANALYSIS OF 3D PRINTING IN HEALTHCARE MARKET FOR ELECTRONIC BEAM MELTING BY COUNTRY, 2020 & 2030 (%)
FIGURE 25.COMPARATIVE SHARE ANALYSIS OF 3D PRINTING IN HEALTHCARE MARKET FOR LAMINATED OBJECT MANUFACTURING BY COUNTRY, 2020 & 2030 (%)
FIGURE 26.COMPARATIVE SHARE ANALYSIS OF 3D PRINTING IN HEALTHCARE MARKET FOR OTHERS BY COUNTRY, 2020 & 2030 (%)
FIGURE 27.COMPARATIVE SHARE ANALYSIS OF 3D PRINTING IN HEALTHCARE MARKET FOR EXTERNAL WEARABLE DEVICES BY COUNTRY, 2020 & 2030 (%)
FIGURE 28.COMPARATIVE SHARE ANALYSIS OF 3D PRINTING IN HEALTHCARE MARKET FOR CLINICAL STUDY DEVICES BY COUNTRY, 2020 & 2030 (%)
FIGURE 29.COMPARATIVE SHARE ANALYSIS OF 3D PRINTING IN HEALTHCARE MARKET FOR IMPLANTS BY COUNTRY, 2020 & 2030 (%)
FIGURE 30.COMPARATIVE SHARE ANALYSIS OF 3D PRINTING IN HEALTHCARE MARKET FOR TISSUE ENGINEERING BY COUNTRY, 2020 & 2030 (%)
FIGURE 31.COMPARATIVE SHARE ANALYSIS OF 3D PRINTING IN HEALTHCARE MARKET FOR MEDICAL AND SURGICAL CENTRES, BY COUNTRY, 2020 & 2030 (%)
FIGURE 32.COMPARATIVE SHARE ANALYSIS OF 3D PRINTING IN HEALTHCARE MARKET FOR PHARMA & BIOTECH COMPANIES, BY COUNTRY, 2020 & 2030 (%)
FIGURE 33.COMPARATIVE SHARE ANALYSIS OF 3D PRINTING IN HEALTHCARE MARKET FOR ACADEMIC INSTITUTIONS, BY COUNTRY, 2020 & 2030 (%)
FIGURE 34.3D SYSTEMS: NET SALES 2018–2020 ($MILLION)
FIGURE 35.3D SYSTEMS: REVENUE SHARE BY REGION 2020 (%)
FIGURE 36.EXONE COMPANY: NET SALES 2018–2020 ($MILLION)
FIGURE 37.EXONE COMPANY: REVENUE SHARE BY SEGMENT 2020 (%)
FIGURE 38.EXONE COMPANY: REVENUE SHARE BY REGION 2020 (%)
FIGURE 39.GE NET SALES 2018–2020, ($MILLION)
FIGURE 40.GE: REVENUE SHARE BY SEGMENTS 2020 (%)
FIGURE 41.GE: REVENUE SHARE, BY REGION 2020 (%)
FIGURE 42.MATERIALISE: NET SALES 2018–2020 ($MILLION)
FIGURE 43.MATERIALISE: REVENUE SHARE BY SEGMENT 2020(%)
FIGURE 44.MATERIALISE: REVENUE SHARE BY REGION 2020(%)
FIGURE 45.ORGANOVO HOLDINGS: NET SALES 2018–2020 ($MILLION)
FIGURE 46.PROTOLABS: NET SALES 2018–2020 ($MILLION)
FIGURE 48.PROTOLABS: REVENUE SHARE BY SEGMENT 2020(%)
FIGURE 49.PROTOLABS: REVENUE SHARE BY REGION 2020(%)
FIGURE 50.SLM SOLUTIONS: NET SALES 2018–2020 ($MILLION)
FIGURE 51.SLM SOLUTIONS: REVENUE SHARE BY SEGMENT 2020 (%)
FIGURE 52.SLM SOLUTIONS: REVENUE SHARE BY REGION 2020 (%)
FIGURE 53.STRATASYS: REVENUE 2018–2020 ($MILLION)
FIGURE 54.STRATASYS: REVENUE SHARE BY SEGMENT 2020 (%)
FIGURE 55.STRATASYS: REVENUE SHARE BY REGION 2020 (%)


 

 
 

Lysosomal storage disorders are rare conditions caused by an inborn error of metabolism that results in the absence or deficiency of an enzyme, leading to the inappropriate accumulation of material in various cells of the body. Furthermore, this condition is marked by symptoms such as organ enlargement including heart, spleen, and liver. Other symptoms include skin rashes, burning pains in hand and feet, lung dysfunction, damage to central nervous system, and muscle weakness.

Surge of enzyme replacement therapy across the world is majorly attributed to lack or malfunctioning of certain enzymes present in the body. These lysosomal storage disorders are generally genetic in nature and if not diagnosed and treated properly can turn into severe health conditions. Furthermore, increase in government initiatives for production of drugs for ERT and the launch of its pipeline products are anticipated to boost the expansion of the narcolepsy drug market.

Presently, the agalsidase beta dominates the enzyme replacement therapy market, owing to factors such as rise in prevalence of chronic and life-threatening lysosomal storage diseases and government initiatives to increase awareness among people about the availability of ERT. 

North America dominates the global enzyme replacement therapy market in 2020, owing to widespread availability & ease of infusion centers, increase in acceptance of newer therapies and rise in prevalence of enzyme deficiency in the region.

PURCHASE OPTIONS

Start reading instantly ,This Report and over 13000+ thousand more Reports, Available with Avenue Library, T&C*

Call or Email us

U.S.-Canada
Toll-free :
+1-800-792-5285
Int'l : +1-503-894-6022
Europe : + 44-845-528-1300
Email : help@alliedmarketresearch.com
FREQUENTLY ASKED QUESTIONS?
Our Report Looks Like This
 

A. The total market value of Enzyme Replacement Therapy Market is $7,780.69 million in 2020

A. The forecast period in the report is from 2021 to 2030

A. The market value of Enzyme Replacement Therapy Market in 2030 is $15,166.34 Million

A. The base year for the report is 2020

A. Yes, Enzyme Replacement Therapy companies are profiled in the report

A. The top companies that hold the market share in Enzyme Replacement Therapy Market are Sanofi S.A., Pfizer Inc. ,BioMarin Pharmaceutical Inc., Takeda Pharmaceutical Company Limited, AstraZeneca plc, AbbVie Inc., Inc.,Nestlé S.A. (Nestlé Health Science S.A.), Chiesi Farmaceutici S.p.A., Leadiant Biosciences, Inc., and Digestive Care, Inc.

A. No, there is no value chain analysis provided in the Enzyme Replacement Therapy Market report

A. The key trends in the Enzyme Replacement Therapy Market are empowers manufacturers in the medical sector to produce customized products.

Allied Market Research Allied Market Research Allied Market Research
RELATED TAGS
 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
Enzyme Replacement Therapy Market

Start reading instantly.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,712
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $4,125
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $6,168
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,929
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $10,663
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Membership
  • $ 699/mo
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Erythropoietin Drugs Market

Global Opportunity Analysis and Industry Forecast, 2021–2028

Published in May 2021

Download Sample

Protein Therapeutics Market

Global Opportunity Analysis and Industry Forecast, 2017-2023

Published in Nov 2017

Download Sample

Surgical Equipment Market

Global Opportunity Analysis and Industry Forecast, 2020-2027

Published in Jan 2021

Download Sample

Medical Implant Market

Global Opportunity Analysis and Industry Forecast, 2020–2027

Published in Nov 2020

Download Sample

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers